COMPANY / RESEARCH
Research & Insights
FEATURED BOOK
The Science of First
The intellectual framework behind AppliedXL: how public institutional records carry market-moving signals before they become news, and how to read them first.
FEATURED THESIS
Who Will Monetize Truth?
A thesis for the future of information. The news industry isn't declining, it's being repriced, and value is migrating from the content layer to the intelligence layer.
06 JUN 2026AppliedXL Prediction Model: Six Clinical Trial Case Studies with Full ExplainabilitySix clinical trials tracked from first filing to outcome. Each case shows how the model's probability shifted with registry events, and whether the final call matched reality. Covers Roche, Regeneron, Abivax, Akeso, Sanofi, and Praxis.APPLIEDXL RESEARCH · INTERACTIVE11 MAY 2026AppliedXL Response to FDA Drug Repurposing Initiative: 5 Drugs With Clinical Evidence and No Commercial ChampionThe FDA opened a docket on drug repurposing where commercial incentives are too weak to drive new applications. AppliedXL identified five candidates with strong evidence for new indications and no active sponsor.APPLIEDXL RESEARCH · 12 MIN09 MAY 2026Clinical Trial Data as Alpha: Building a Biotech Quant Trading Model With Point-in-Time IntelligenceA biotech quant model built on point-in-time trial data, enriched with SEC filings, press releases, and AI agents. 107 out-of-sample trades, +204% return, 1.32 Sharpe. The alpha the market can't see.WILL KATZKA · 15 MIN15 APR 2026AppliedXL Achieves State-of-the-Art Clinical Trial Prediction With Domain-Specific Agentic AIClinical trials pass through five checkpoints, and failure can concentrate at any one. Our framework predicts where a trial is most likely to fail, reaching 0.873 AUC on endpoint prediction: 17 points above the best published baseline.2 MIN09 APR 2026Vertical AI vs. General AI: AppliedXL's Floor Beats Claude, ChatGPT, and Perplexity's Ceiling on Biopharma Agentic ResearchA head-to-head evaluation of AppliedXL against leading general-purpose AI on real biopharma research tasks, measuring accuracy, citation quality, and depth across 20 structured queries.12 MIN07 DEC 2024Seeing Risk Before It Becomes NewsExecution failures rarely appear suddenly. They build quietly inside clinical programs until they reach earnings calls or headlines. AppliedXL identifies operational risk long before it becomes public.8 MIN07 DEC 2024AppliedXL Partners with Bloomberg to Integrate Real-Time Biotech IntelligenceBloomberg Terminal users now have access to AppliedXL's AI-generated coverage of clinical trials, designed to identify catalyst events in the pharmaceutical industry as they develop.5 MIN07 DEC 2024Systematic Trading Strategies in Biotech: Early Risk Signals for Alpha GenerationHow structured clinical-trial event data can support alpha generation through early instability detection, mechanistic readthrough, and volatility mispricing.14 MIN07 DEC 2024Spillover Risk and Readthrough Alpha: A Quantitative AnalysisRegistry anomalies precede press releases by 48 to 72 hours. This examines mechanistic linkages and asset repricing across 2023 to 2025 catalyst events.10 MIN07 DEC 2024AppliedXL and Bain Introduce a New Operating Discipline for PharmaA combined framework that pairs real-time AI monitoring with strategic analysis, turning clinical-trial execution into a measurable operational advantage.8 MIN06 DEC 2024The Hidden Signals That Decide Drug Success or FailureAppliedXL decodes subtle shifts in clinical trials, flagging risks and opportunities before they hit the news cycle.6 MIN